Nirsevimab Disease Interactions
There is 1 disease interaction with nirsevimab.
Moderate
Nirsevimab (applies to nirsevimab) Bleeding disorder
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding Associated with Coagulation Defect
Nirsevimab should be given with caution to infants and children with clinically significant bleeding disorders such as thrombocytopenia or any coagulation disorder.
References (2)
- (2023) "Product Information. Beyfortus (cvx 307) (nirsevimab (cvx 307))." sanofi pasteur
- (2023) "Product Information. Beyfortus (cvx 306) (nirsevimab (cvx 306))." sanofi pasteur
Switch to consumer interaction data
Nirsevimab drug interactions
There are 3 drug interactions with nirsevimab.
More about nirsevimab
- nirsevimab consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: antiviral monoclonal antibodies
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.